Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tarceva in Combination With Oxaliplatin and Capecitabine in Stage IV Colorectal Cancer
NCT00123851Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Mar 2003
- Primary completion
- Aug 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of erlotinib in colorectal cancer (CRC), sponsored by Dana-Farber Cancer Institute. Primary endpoint: Objective Response Rate. Started Mar 2003; status: completed.
02
Drugs
erlotinib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT00123851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00123851.